nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—ABL1—liver cancer	0.125	0.362	CbGaD
Vandetanib—KDR—liver cancer	0.106	0.307	CbGaD
Vandetanib—VEGFA—liver cancer	0.0901	0.261	CbGaD
Vandetanib—MKNK1—Sorafenib—liver cancer	0.0597	0.128	CbGbCtD
Vandetanib—FLT4—Sorafenib—liver cancer	0.0499	0.107	CbGbCtD
Vandetanib—FLT3—Sorafenib—liver cancer	0.0431	0.0925	CbGbCtD
Vandetanib—KDR—Sorafenib—liver cancer	0.0431	0.0925	CbGbCtD
Vandetanib—RET—Sorafenib—liver cancer	0.0431	0.0925	CbGbCtD
Vandetanib—EPHB6—Sorafenib—liver cancer	0.0381	0.0818	CbGbCtD
Vandetanib—EPHA6—Sorafenib—liver cancer	0.0381	0.0818	CbGbCtD
Vandetanib—STK10—Sorafenib—liver cancer	0.0343	0.0735	CbGbCtD
Vandetanib—PDGFRB—Sorafenib—liver cancer	0.0312	0.0669	CbGbCtD
Vandetanib—MAP2K5—Sorafenib—liver cancer	0.0312	0.0669	CbGbCtD
Vandetanib—MAP3K19—Sorafenib—liver cancer	0.0287	0.0615	CbGbCtD
Vandetanib—ALB—liver cancer	0.0242	0.0701	CbGaD
Vandetanib—ABCC1—Epirubicin—liver cancer	0.00966	0.0207	CbGbCtD
Vandetanib—ABCG2—Sorafenib—liver cancer	0.00566	0.0121	CbGbCtD
Vandetanib—ABCC1—Doxorubicin—liver cancer	0.00513	0.011	CbGbCtD
Vandetanib—ABCG2—Doxorubicin—liver cancer	0.00343	0.00736	CbGbCtD
Vandetanib—ORM1—bile—liver cancer	0.0024	0.11	CbGeAlD
Vandetanib—KDR—umbilical vein—liver cancer	0.002	0.0911	CbGeAlD
Vandetanib—CYP3A4—Sorafenib—liver cancer	0.00122	0.00262	CbGbCtD
Vandetanib—Bosutinib—TNK2—liver cancer	0.000857	0.241	CrCbGaD
Vandetanib—Bosutinib—SRMS—liver cancer	0.000857	0.241	CrCbGaD
Vandetanib—FLT4—embryo—liver cancer	0.000793	0.0361	CbGeAlD
Vandetanib—ERBB3—embryo—liver cancer	0.000755	0.0344	CbGeAlD
Vandetanib—CYP3A4—Doxorubicin—liver cancer	0.000742	0.00159	CbGbCtD
Vandetanib—PDGFRB—gall bladder—liver cancer	0.000711	0.0324	CbGeAlD
Vandetanib—FGR—embryo—liver cancer	0.0007	0.0319	CbGeAlD
Vandetanib—RET—embryo—liver cancer	0.0007	0.0319	CbGeAlD
Vandetanib—ORM1—gall bladder—liver cancer	0.000667	0.0304	CbGeAlD
Vandetanib—Afatinib—ABL1—liver cancer	0.000667	0.187	CrCbGaD
Vandetanib—FYN—embryo—liver cancer	0.000652	0.0297	CbGeAlD
Vandetanib—TEK—embryo—liver cancer	0.000637	0.0291	CbGeAlD
Vandetanib—ALB—gall bladder—liver cancer	0.000585	0.0267	CbGeAlD
Vandetanib—SRC—embryo—liver cancer	0.000566	0.0258	CbGeAlD
Vandetanib—KDR—embryo—liver cancer	0.000521	0.0238	CbGeAlD
Vandetanib—LYN—liver—liver cancer	0.000472	0.0215	CbGeAlD
Vandetanib—Erlotinib—ABL1—liver cancer	0.000471	0.132	CrCbGaD
Vandetanib—PDGFRB—embryo—liver cancer	0.000451	0.0206	CbGeAlD
Vandetanib—FLT3—liver—liver cancer	0.000404	0.0184	CbGeAlD
Vandetanib—ABL1—embryo—liver cancer	0.000402	0.0183	CbGeAlD
Vandetanib—STK35—liver—liver cancer	0.000395	0.018	CbGeAlD
Vandetanib—ABL2—liver—liver cancer	0.000385	0.0176	CbGeAlD
Vandetanib—EGFR—liver—liver cancer	0.000376	0.0171	CbGeAlD
Vandetanib—FLT4—liver—liver cancer	0.000367	0.0167	CbGeAlD
Vandetanib—RIPK2—liver—liver cancer	0.000365	0.0166	CbGeAlD
Vandetanib—VEGFA—liver—liver cancer	0.000364	0.0166	CbGeAlD
Vandetanib—FMO1—liver—liver cancer	0.000362	0.0165	CbGeAlD
Vandetanib—IRAK4—liver—liver cancer	0.000356	0.0162	CbGeAlD
Vandetanib—ERBB3—liver—liver cancer	0.000349	0.0159	CbGeAlD
Vandetanib—MKNK1—liver—liver cancer	0.000328	0.0149	CbGeAlD
Vandetanib—LCK—liver—liver cancer	0.000324	0.0148	CbGeAlD
Vandetanib—FGR—liver—liver cancer	0.000324	0.0148	CbGeAlD
Vandetanib—AXL—liver—liver cancer	0.000322	0.0147	CbGeAlD
Vandetanib—FMO3—liver—liver cancer	0.000313	0.0142	CbGeAlD
Vandetanib—SLK—liver—liver cancer	0.00031	0.0141	CbGeAlD
Vandetanib—FYN—liver—liver cancer	0.000302	0.0138	CbGeAlD
Vandetanib—MAP4K5—liver—liver cancer	0.000295	0.0134	CbGeAlD
Vandetanib—TEK—liver—liver cancer	0.000295	0.0134	CbGeAlD
Vandetanib—Bosutinib—ABL1—liver cancer	0.00029	0.0816	CrCbGaD
Vandetanib—YES1—liver—liver cancer	0.000272	0.0124	CbGeAlD
Vandetanib—STK10—liver—liver cancer	0.00027	0.0123	CbGeAlD
Vandetanib—SRC—liver—liver cancer	0.000262	0.0119	CbGeAlD
Vandetanib—MAP2K5—liver—liver cancer	0.000241	0.011	CbGeAlD
Vandetanib—KDR—liver—liver cancer	0.000241	0.011	CbGeAlD
Vandetanib—PLK4—Doxorubicin—Epirubicin—liver cancer	0.000229	0.115	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Epirubicin—liver cancer	0.000229	0.115	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Doxorubicin—liver cancer	0.000212	0.106	CbGdCrCtD
Vandetanib—PLK4—Epirubicin—Doxorubicin—liver cancer	0.000212	0.106	CbGdCrCtD
Vandetanib—Erythema multiforme—Sorafenib—liver cancer	0.000212	0.00397	CcSEcCtD
Vandetanib—Skin ulcer—Epirubicin—liver cancer	0.000212	0.00397	CcSEcCtD
Vandetanib—Laryngitis—Doxorubicin—liver cancer	0.000212	0.00396	CcSEcCtD
Vandetanib—PDGFRB—liver—liver cancer	0.000209	0.00951	CbGeAlD
Vandetanib—Cardiac disorder—Sorafenib—liver cancer	0.000208	0.00389	CcSEcCtD
Vandetanib—Haemoptysis—Doxorubicin—liver cancer	0.000206	0.00386	CcSEcCtD
Vandetanib—Ventricular arrhythmia—Doxorubicin—liver cancer	0.000206	0.00386	CcSEcCtD
Vandetanib—Angiopathy—Sorafenib—liver cancer	0.000203	0.00381	CcSEcCtD
Vandetanib—Mediastinal disorder—Sorafenib—liver cancer	0.000202	0.00378	CcSEcCtD
Vandetanib—Arrhythmia—Sorafenib—liver cancer	0.0002	0.00375	CcSEcCtD
Vandetanib—Alopecia—Sorafenib—liver cancer	0.000198	0.00371	CcSEcCtD
Vandetanib—Fungal infection—Doxorubicin—liver cancer	0.000198	0.0037	CcSEcCtD
Vandetanib—Mental disorder—Sorafenib—liver cancer	0.000196	0.00368	CcSEcCtD
Vandetanib—Skin ulcer—Doxorubicin—liver cancer	0.000196	0.00367	CcSEcCtD
Vandetanib—ORM1—liver—liver cancer	0.000196	0.00892	CbGeAlD
Vandetanib—Malnutrition—Sorafenib—liver cancer	0.000195	0.00365	CcSEcCtD
Vandetanib—ABL1—Idarubicin—Epirubicin—liver cancer	0.000193	0.0966	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Epirubicin—liver cancer	0.000193	0.0966	CbGdCrCtD
Vandetanib—ABL1—Doxorubicin—Epirubicin—liver cancer	0.000193	0.0966	CbGdCrCtD
Vandetanib—Dysgeusia—Sorafenib—liver cancer	0.000191	0.00358	CcSEcCtD
Vandetanib—Muscle spasms—Sorafenib—liver cancer	0.000187	0.00351	CcSEcCtD
Vandetanib—ABL1—liver—liver cancer	0.000186	0.00847	CbGeAlD
Vandetanib—Cellulitis—Epirubicin—liver cancer	0.000181	0.0034	CcSEcCtD
Vandetanib—Hypocalcaemia—Epirubicin—liver cancer	0.00018	0.00337	CcSEcCtD
Vandetanib—ABL1—Epirubicin—Doxorubicin—liver cancer	0.000178	0.0894	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Doxorubicin—liver cancer	0.000178	0.0894	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Doxorubicin—liver cancer	0.000178	0.0894	CbGdCrCtD
Vandetanib—Blood bilirubin increased—Epirubicin—liver cancer	0.000174	0.00327	CcSEcCtD
Vandetanib—Creatinine increased—Epirubicin—liver cancer	0.000173	0.00324	CcSEcCtD
Vandetanib—ALB—liver—liver cancer	0.000172	0.00782	CbGeAlD
Vandetanib—Loss of consciousness—Sorafenib—liver cancer	0.000171	0.00321	CcSEcCtD
Vandetanib—Cough—Sorafenib—liver cancer	0.00017	0.00319	CcSEcCtD
Vandetanib—Hypertension—Sorafenib—liver cancer	0.000168	0.00315	CcSEcCtD
Vandetanib—Cellulitis—Doxorubicin—liver cancer	0.000168	0.00314	CcSEcCtD
Vandetanib—Hypocalcaemia—Doxorubicin—liver cancer	0.000167	0.00312	CcSEcCtD
Vandetanib—Arthralgia—Sorafenib—liver cancer	0.000166	0.00311	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000165	0.00309	CcSEcCtD
Vandetanib—Erlotinib—CYP1A1—liver cancer	0.000164	0.0461	CrCbGaD
Vandetanib—Dry mouth—Sorafenib—liver cancer	0.000162	0.00304	CcSEcCtD
Vandetanib—Blood bilirubin increased—Doxorubicin—liver cancer	0.000161	0.00302	CcSEcCtD
Vandetanib—Cystitis noninfective—Epirubicin—liver cancer	0.000161	0.00302	CcSEcCtD
Vandetanib—Creatinine increased—Doxorubicin—liver cancer	0.00016	0.003	CcSEcCtD
Vandetanib—Cystitis—Epirubicin—liver cancer	0.000159	0.00298	CcSEcCtD
Vandetanib—Colitis—Epirubicin—liver cancer	0.000158	0.00297	CcSEcCtD
Vandetanib—Infection—Sorafenib—liver cancer	0.000158	0.00296	CcSEcCtD
Vandetanib—Nervous system disorder—Sorafenib—liver cancer	0.000156	0.00292	CcSEcCtD
Vandetanib—Thrombocytopenia—Sorafenib—liver cancer	0.000156	0.00292	CcSEcCtD
Vandetanib—Skin disorder—Sorafenib—liver cancer	0.000155	0.0029	CcSEcCtD
Vandetanib—Dry eye—Epirubicin—liver cancer	0.000152	0.00285	CcSEcCtD
Vandetanib—Neoplasm—Epirubicin—liver cancer	0.000149	0.00279	CcSEcCtD
Vandetanib—Bladder pain—Epirubicin—liver cancer	0.000149	0.00279	CcSEcCtD
Vandetanib—Cystitis noninfective—Doxorubicin—liver cancer	0.000149	0.00279	CcSEcCtD
Vandetanib—Cystitis—Doxorubicin—liver cancer	0.000147	0.00276	CcSEcCtD
Vandetanib—Colitis—Doxorubicin—liver cancer	0.000146	0.00274	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000145	0.00272	CcSEcCtD
Vandetanib—Sepsis—Epirubicin—liver cancer	0.000143	0.00268	CcSEcCtD
Vandetanib—Dyspnoea—Sorafenib—liver cancer	0.000142	0.00266	CcSEcCtD
Vandetanib—ABCC1—liver—liver cancer	0.000142	0.00646	CbGeAlD
Vandetanib—Dry eye—Doxorubicin—liver cancer	0.000141	0.00264	CcSEcCtD
Vandetanib—Dyspepsia—Sorafenib—liver cancer	0.00014	0.00262	CcSEcCtD
Vandetanib—Decreased appetite—Sorafenib—liver cancer	0.000138	0.00259	CcSEcCtD
Vandetanib—Bladder pain—Doxorubicin—liver cancer	0.000138	0.00258	CcSEcCtD
Vandetanib—Neoplasm—Doxorubicin—liver cancer	0.000138	0.00258	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Sorafenib—liver cancer	0.000137	0.00257	CcSEcCtD
Vandetanib—Fatigue—Sorafenib—liver cancer	0.000137	0.00257	CcSEcCtD
Vandetanib—Pain—Sorafenib—liver cancer	0.000136	0.00255	CcSEcCtD
Vandetanib—Constipation—Sorafenib—liver cancer	0.000136	0.00255	CcSEcCtD
Vandetanib—Sepsis—Doxorubicin—liver cancer	0.000132	0.00248	CcSEcCtD
Vandetanib—Gastrointestinal pain—Sorafenib—liver cancer	0.00013	0.00244	CcSEcCtD
Vandetanib—Abdominal pain—Sorafenib—liver cancer	0.000126	0.00236	CcSEcCtD
Vandetanib—Body temperature increased—Sorafenib—liver cancer	0.000126	0.00236	CcSEcCtD
Vandetanib—Dermatitis bullous—Epirubicin—liver cancer	0.000125	0.00235	CcSEcCtD
Vandetanib—Cardiac failure—Epirubicin—liver cancer	0.000123	0.0023	CcSEcCtD
Vandetanib—Hypoglycaemia—Epirubicin—liver cancer	0.000123	0.0023	CcSEcCtD
Vandetanib—Lethargy—Epirubicin—liver cancer	0.000122	0.00229	CcSEcCtD
Vandetanib—Hyponatraemia—Epirubicin—liver cancer	0.00012	0.00225	CcSEcCtD
Vandetanib—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.00012	0.00224	CcSEcCtD
Vandetanib—ABCG2—liver—liver cancer	0.000117	0.00534	CbGeAlD
Vandetanib—Dermatitis bullous—Doxorubicin—liver cancer	0.000116	0.00217	CcSEcCtD
Vandetanib—Asthenia—Sorafenib—liver cancer	0.000114	0.00214	CcSEcCtD
Vandetanib—Cardiac arrest—Epirubicin—liver cancer	0.000114	0.00213	CcSEcCtD
Vandetanib—Cardiac failure—Doxorubicin—liver cancer	0.000113	0.00213	CcSEcCtD
Vandetanib—Hypoglycaemia—Doxorubicin—liver cancer	0.000113	0.00213	CcSEcCtD
Vandetanib—Lethargy—Doxorubicin—liver cancer	0.000113	0.00212	CcSEcCtD
Vandetanib—Pruritus—Sorafenib—liver cancer	0.000113	0.00211	CcSEcCtD
Vandetanib—Blood creatinine increased—Epirubicin—liver cancer	0.000112	0.0021	CcSEcCtD
Vandetanib—Dehydration—Epirubicin—liver cancer	0.000111	0.00208	CcSEcCtD
Vandetanib—Hyponatraemia—Doxorubicin—liver cancer	0.000111	0.00208	CcSEcCtD
Vandetanib—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000111	0.00207	CcSEcCtD
Vandetanib—Dry skin—Epirubicin—liver cancer	0.00011	0.00205	CcSEcCtD
Vandetanib—Hypokalaemia—Epirubicin—liver cancer	0.000109	0.00204	CcSEcCtD
Vandetanib—Diarrhoea—Sorafenib—liver cancer	0.000109	0.00204	CcSEcCtD
Vandetanib—Nasopharyngitis—Epirubicin—liver cancer	0.000107	0.002	CcSEcCtD
Vandetanib—Gastritis—Epirubicin—liver cancer	0.000106	0.00198	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000106	0.00198	CcSEcCtD
Vandetanib—Cardiac arrest—Doxorubicin—liver cancer	0.000105	0.00197	CcSEcCtD
Vandetanib—Dizziness—Sorafenib—liver cancer	0.000105	0.00197	CcSEcCtD
Vandetanib—Blood creatinine increased—Doxorubicin—liver cancer	0.000104	0.00194	CcSEcCtD
Vandetanib—Dysphagia—Epirubicin—liver cancer	0.000103	0.00194	CcSEcCtD
Vandetanib—Influenza—Epirubicin—liver cancer	0.000103	0.00194	CcSEcCtD
Vandetanib—Dehydration—Doxorubicin—liver cancer	0.000103	0.00193	CcSEcCtD
Vandetanib—Gefitinib—CYP1A1—liver cancer	0.000103	0.0288	CrCbGaD
Vandetanib—Dry skin—Doxorubicin—liver cancer	0.000101	0.0019	CcSEcCtD
Vandetanib—Pancreatitis—Epirubicin—liver cancer	0.000101	0.0019	CcSEcCtD
Vandetanib—Vomiting—Sorafenib—liver cancer	0.000101	0.0019	CcSEcCtD
Vandetanib—Hypokalaemia—Doxorubicin—liver cancer	0.000101	0.00189	CcSEcCtD
Vandetanib—Rash—Sorafenib—liver cancer	0.0001	0.00188	CcSEcCtD
Vandetanib—Dermatitis—Sorafenib—liver cancer	0.0001	0.00188	CcSEcCtD
Vandetanib—Headache—Sorafenib—liver cancer	9.97e-05	0.00187	CcSEcCtD
Vandetanib—Bronchitis—Epirubicin—liver cancer	9.95e-05	0.00186	CcSEcCtD
Vandetanib—Nasopharyngitis—Doxorubicin—liver cancer	9.9e-05	0.00185	CcSEcCtD
Vandetanib—Gastritis—Doxorubicin—liver cancer	9.8e-05	0.00184	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Doxorubicin—liver cancer	9.77e-05	0.00183	CcSEcCtD
Vandetanib—Dysuria—Epirubicin—liver cancer	9.67e-05	0.00181	CcSEcCtD
Vandetanib—Neutropenia—Epirubicin—liver cancer	9.67e-05	0.00181	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Epirubicin—liver cancer	9.61e-05	0.0018	CcSEcCtD
Vandetanib—Dysphagia—Doxorubicin—liver cancer	9.57e-05	0.00179	CcSEcCtD
Vandetanib—Influenza—Doxorubicin—liver cancer	9.57e-05	0.00179	CcSEcCtD
Vandetanib—Pollakiuria—Epirubicin—liver cancer	9.56e-05	0.00179	CcSEcCtD
Vandetanib—Nausea—Sorafenib—liver cancer	9.45e-05	0.00177	CcSEcCtD
Vandetanib—Photosensitivity reaction—Epirubicin—liver cancer	9.44e-05	0.00177	CcSEcCtD
Vandetanib—Pancreatitis—Doxorubicin—liver cancer	9.38e-05	0.00176	CcSEcCtD
Vandetanib—Weight decreased—Epirubicin—liver cancer	9.36e-05	0.00175	CcSEcCtD
Vandetanib—Hyperglycaemia—Epirubicin—liver cancer	9.33e-05	0.00175	CcSEcCtD
Vandetanib—Pneumonia—Epirubicin—liver cancer	9.28e-05	0.00174	CcSEcCtD
Vandetanib—Infestation NOS—Epirubicin—liver cancer	9.22e-05	0.00173	CcSEcCtD
Vandetanib—Infestation—Epirubicin—liver cancer	9.22e-05	0.00173	CcSEcCtD
Vandetanib—Bronchitis—Doxorubicin—liver cancer	9.2e-05	0.00172	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Epirubicin—liver cancer	9.14e-05	0.00171	CcSEcCtD
Vandetanib—Erlotinib—ALB—liver cancer	9.13e-05	0.0257	CrCbGaD
Vandetanib—Renal failure—Epirubicin—liver cancer	9.07e-05	0.0017	CcSEcCtD
Vandetanib—Stomatitis—Epirubicin—liver cancer	8.99e-05	0.00168	CcSEcCtD
Vandetanib—Urinary tract infection—Epirubicin—liver cancer	8.96e-05	0.00168	CcSEcCtD
Vandetanib—Conjunctivitis—Epirubicin—liver cancer	8.96e-05	0.00168	CcSEcCtD
Vandetanib—Dysuria—Doxorubicin—liver cancer	8.95e-05	0.00168	CcSEcCtD
Vandetanib—Neutropenia—Doxorubicin—liver cancer	8.95e-05	0.00168	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Doxorubicin—liver cancer	8.89e-05	0.00167	CcSEcCtD
Vandetanib—Pollakiuria—Doxorubicin—liver cancer	8.84e-05	0.00166	CcSEcCtD
Vandetanib—Haematuria—Epirubicin—liver cancer	8.79e-05	0.00165	CcSEcCtD
Vandetanib—Photosensitivity reaction—Doxorubicin—liver cancer	8.74e-05	0.00164	CcSEcCtD
Vandetanib—Hepatobiliary disease—Epirubicin—liver cancer	8.72e-05	0.00163	CcSEcCtD
Vandetanib—Epistaxis—Epirubicin—liver cancer	8.7e-05	0.00163	CcSEcCtD
Vandetanib—Weight decreased—Doxorubicin—liver cancer	8.66e-05	0.00162	CcSEcCtD
Vandetanib—Sinusitis—Epirubicin—liver cancer	8.65e-05	0.00162	CcSEcCtD
Vandetanib—Hyperglycaemia—Doxorubicin—liver cancer	8.63e-05	0.00162	CcSEcCtD
Vandetanib—Pneumonia—Doxorubicin—liver cancer	8.58e-05	0.00161	CcSEcCtD
Vandetanib—Infestation—Doxorubicin—liver cancer	8.53e-05	0.0016	CcSEcCtD
Vandetanib—Infestation NOS—Doxorubicin—liver cancer	8.53e-05	0.0016	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Doxorubicin—liver cancer	8.46e-05	0.00158	CcSEcCtD
Vandetanib—Bradycardia—Epirubicin—liver cancer	8.43e-05	0.00158	CcSEcCtD
Vandetanib—Renal failure—Doxorubicin—liver cancer	8.39e-05	0.00157	CcSEcCtD
Vandetanib—Haemoglobin—Epirubicin—liver cancer	8.32e-05	0.00156	CcSEcCtD
Vandetanib—Stomatitis—Doxorubicin—liver cancer	8.32e-05	0.00156	CcSEcCtD
Vandetanib—Urinary tract infection—Doxorubicin—liver cancer	8.29e-05	0.00155	CcSEcCtD
Vandetanib—Conjunctivitis—Doxorubicin—liver cancer	8.29e-05	0.00155	CcSEcCtD
Vandetanib—Haemorrhage—Epirubicin—liver cancer	8.28e-05	0.00155	CcSEcCtD
Vandetanib—Urinary tract disorder—Epirubicin—liver cancer	8.18e-05	0.00153	CcSEcCtD
Vandetanib—CYP3A4—liver—liver cancer	8.17e-05	0.00372	CbGeAlD
Vandetanib—Haematuria—Doxorubicin—liver cancer	8.14e-05	0.00152	CcSEcCtD
Vandetanib—Urethral disorder—Epirubicin—liver cancer	8.12e-05	0.00152	CcSEcCtD
Vandetanib—Hepatobiliary disease—Doxorubicin—liver cancer	8.07e-05	0.00151	CcSEcCtD
Vandetanib—Epistaxis—Doxorubicin—liver cancer	8.05e-05	0.00151	CcSEcCtD
Vandetanib—Sinusitis—Doxorubicin—liver cancer	8.01e-05	0.0015	CcSEcCtD
Vandetanib—Visual impairment—Epirubicin—liver cancer	7.98e-05	0.00149	CcSEcCtD
Vandetanib—Erythema multiforme—Epirubicin—liver cancer	7.83e-05	0.00147	CcSEcCtD
Vandetanib—Bradycardia—Doxorubicin—liver cancer	7.8e-05	0.00146	CcSEcCtD
Vandetanib—Eye disorder—Epirubicin—liver cancer	7.74e-05	0.00145	CcSEcCtD
Vandetanib—Haemoglobin—Doxorubicin—liver cancer	7.7e-05	0.00144	CcSEcCtD
Vandetanib—Cardiac disorder—Epirubicin—liver cancer	7.68e-05	0.00144	CcSEcCtD
Vandetanib—Haemorrhage—Doxorubicin—liver cancer	7.66e-05	0.00144	CcSEcCtD
Vandetanib—Urinary tract disorder—Doxorubicin—liver cancer	7.57e-05	0.00142	CcSEcCtD
Vandetanib—Angiopathy—Epirubicin—liver cancer	7.51e-05	0.00141	CcSEcCtD
Vandetanib—Urethral disorder—Doxorubicin—liver cancer	7.51e-05	0.00141	CcSEcCtD
Vandetanib—Mediastinal disorder—Epirubicin—liver cancer	7.46e-05	0.0014	CcSEcCtD
Vandetanib—Arrhythmia—Epirubicin—liver cancer	7.4e-05	0.00139	CcSEcCtD
Vandetanib—Visual impairment—Doxorubicin—liver cancer	7.38e-05	0.00138	CcSEcCtD
Vandetanib—Alopecia—Epirubicin—liver cancer	7.32e-05	0.00137	CcSEcCtD
Vandetanib—Mental disorder—Epirubicin—liver cancer	7.25e-05	0.00136	CcSEcCtD
Vandetanib—Erythema multiforme—Doxorubicin—liver cancer	7.24e-05	0.00136	CcSEcCtD
Vandetanib—Malnutrition—Epirubicin—liver cancer	7.21e-05	0.00135	CcSEcCtD
Vandetanib—Eye disorder—Doxorubicin—liver cancer	7.16e-05	0.00134	CcSEcCtD
Vandetanib—Cardiac disorder—Doxorubicin—liver cancer	7.11e-05	0.00133	CcSEcCtD
Vandetanib—Dysgeusia—Epirubicin—liver cancer	7.06e-05	0.00132	CcSEcCtD
Vandetanib—Angiopathy—Doxorubicin—liver cancer	6.95e-05	0.0013	CcSEcCtD
Vandetanib—Muscle spasms—Epirubicin—liver cancer	6.93e-05	0.0013	CcSEcCtD
Vandetanib—Mediastinal disorder—Doxorubicin—liver cancer	6.9e-05	0.00129	CcSEcCtD
Vandetanib—Arrhythmia—Doxorubicin—liver cancer	6.84e-05	0.00128	CcSEcCtD
Vandetanib—Vision blurred—Epirubicin—liver cancer	6.79e-05	0.00127	CcSEcCtD
Vandetanib—Alopecia—Doxorubicin—liver cancer	6.77e-05	0.00127	CcSEcCtD
Vandetanib—Mental disorder—Doxorubicin—liver cancer	6.71e-05	0.00126	CcSEcCtD
Vandetanib—Malnutrition—Doxorubicin—liver cancer	6.67e-05	0.00125	CcSEcCtD
Vandetanib—Dysgeusia—Doxorubicin—liver cancer	6.53e-05	0.00122	CcSEcCtD
Vandetanib—Muscle spasms—Doxorubicin—liver cancer	6.41e-05	0.0012	CcSEcCtD
Vandetanib—Loss of consciousness—Epirubicin—liver cancer	6.33e-05	0.00119	CcSEcCtD
Vandetanib—Cough—Epirubicin—liver cancer	6.29e-05	0.00118	CcSEcCtD
Vandetanib—Vision blurred—Doxorubicin—liver cancer	6.28e-05	0.00118	CcSEcCtD
Vandetanib—Convulsion—Epirubicin—liver cancer	6.24e-05	0.00117	CcSEcCtD
Vandetanib—Hypertension—Epirubicin—liver cancer	6.22e-05	0.00117	CcSEcCtD
Vandetanib—Arthralgia—Epirubicin—liver cancer	6.14e-05	0.00115	CcSEcCtD
Vandetanib—Chest pain—Epirubicin—liver cancer	6.14e-05	0.00115	CcSEcCtD
Vandetanib—Anxiety—Epirubicin—liver cancer	6.11e-05	0.00115	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	6.09e-05	0.00114	CcSEcCtD
Vandetanib—Dry mouth—Epirubicin—liver cancer	6e-05	0.00112	CcSEcCtD
Vandetanib—Oedema—Epirubicin—liver cancer	5.88e-05	0.0011	CcSEcCtD
Vandetanib—Loss of consciousness—Doxorubicin—liver cancer	5.86e-05	0.0011	CcSEcCtD
Vandetanib—Infection—Epirubicin—liver cancer	5.84e-05	0.00109	CcSEcCtD
Vandetanib—Cough—Doxorubicin—liver cancer	5.82e-05	0.00109	CcSEcCtD
Vandetanib—Convulsion—Doxorubicin—liver cancer	5.78e-05	0.00108	CcSEcCtD
Vandetanib—Nervous system disorder—Epirubicin—liver cancer	5.77e-05	0.00108	CcSEcCtD
Vandetanib—Thrombocytopenia—Epirubicin—liver cancer	5.76e-05	0.00108	CcSEcCtD
Vandetanib—Hypertension—Doxorubicin—liver cancer	5.76e-05	0.00108	CcSEcCtD
Vandetanib—Skin disorder—Epirubicin—liver cancer	5.71e-05	0.00107	CcSEcCtD
Vandetanib—Gefitinib—ALB—liver cancer	5.71e-05	0.0161	CrCbGaD
Vandetanib—Arthralgia—Doxorubicin—liver cancer	5.68e-05	0.00106	CcSEcCtD
Vandetanib—Chest pain—Doxorubicin—liver cancer	5.68e-05	0.00106	CcSEcCtD
Vandetanib—Anxiety—Doxorubicin—liver cancer	5.66e-05	0.00106	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	5.64e-05	0.00106	CcSEcCtD
Vandetanib—Dry mouth—Doxorubicin—liver cancer	5.55e-05	0.00104	CcSEcCtD
Vandetanib—Oedema—Doxorubicin—liver cancer	5.44e-05	0.00102	CcSEcCtD
Vandetanib—Infection—Doxorubicin—liver cancer	5.41e-05	0.00101	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Epirubicin—liver cancer	5.36e-05	0.001	CcSEcCtD
Vandetanib—Nervous system disorder—Doxorubicin—liver cancer	5.34e-05	0.001	CcSEcCtD
Vandetanib—Thrombocytopenia—Doxorubicin—liver cancer	5.33e-05	0.000998	CcSEcCtD
Vandetanib—Insomnia—Epirubicin—liver cancer	5.32e-05	0.000997	CcSEcCtD
Vandetanib—Skin disorder—Doxorubicin—liver cancer	5.29e-05	0.00099	CcSEcCtD
Vandetanib—Paraesthesia—Epirubicin—liver cancer	5.28e-05	0.000989	CcSEcCtD
Vandetanib—Dyspnoea—Epirubicin—liver cancer	5.24e-05	0.000982	CcSEcCtD
Vandetanib—Dyspepsia—Epirubicin—liver cancer	5.18e-05	0.00097	CcSEcCtD
Vandetanib—Decreased appetite—Epirubicin—liver cancer	5.11e-05	0.000958	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Epirubicin—liver cancer	5.08e-05	0.000951	CcSEcCtD
Vandetanib—Fatigue—Epirubicin—liver cancer	5.07e-05	0.00095	CcSEcCtD
Vandetanib—Pain—Epirubicin—liver cancer	5.03e-05	0.000942	CcSEcCtD
Vandetanib—Constipation—Epirubicin—liver cancer	5.03e-05	0.000942	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Doxorubicin—liver cancer	4.96e-05	0.000929	CcSEcCtD
Vandetanib—Insomnia—Doxorubicin—liver cancer	4.92e-05	0.000922	CcSEcCtD
Vandetanib—Paraesthesia—Doxorubicin—liver cancer	4.89e-05	0.000915	CcSEcCtD
Vandetanib—Dyspnoea—Doxorubicin—liver cancer	4.85e-05	0.000909	CcSEcCtD
Vandetanib—Gastrointestinal pain—Epirubicin—liver cancer	4.81e-05	0.000901	CcSEcCtD
Vandetanib—Dyspepsia—Doxorubicin—liver cancer	4.79e-05	0.000897	CcSEcCtD
Vandetanib—Decreased appetite—Doxorubicin—liver cancer	4.73e-05	0.000886	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Doxorubicin—liver cancer	4.7e-05	0.00088	CcSEcCtD
Vandetanib—Fatigue—Doxorubicin—liver cancer	4.69e-05	0.000879	CcSEcCtD
Vandetanib—Pain—Doxorubicin—liver cancer	4.65e-05	0.000872	CcSEcCtD
Vandetanib—Constipation—Doxorubicin—liver cancer	4.65e-05	0.000872	CcSEcCtD
Vandetanib—Abdominal pain—Epirubicin—liver cancer	4.65e-05	0.000871	CcSEcCtD
Vandetanib—Body temperature increased—Epirubicin—liver cancer	4.65e-05	0.000871	CcSEcCtD
Vandetanib—Gastrointestinal pain—Doxorubicin—liver cancer	4.45e-05	0.000834	CcSEcCtD
Vandetanib—Abdominal pain—Doxorubicin—liver cancer	4.3e-05	0.000806	CcSEcCtD
Vandetanib—Body temperature increased—Doxorubicin—liver cancer	4.3e-05	0.000806	CcSEcCtD
Vandetanib—Asthenia—Epirubicin—liver cancer	4.22e-05	0.000791	CcSEcCtD
Vandetanib—Pruritus—Epirubicin—liver cancer	4.16e-05	0.00078	CcSEcCtD
Vandetanib—Diarrhoea—Epirubicin—liver cancer	4.02e-05	0.000754	CcSEcCtD
Vandetanib—Asthenia—Doxorubicin—liver cancer	3.9e-05	0.000731	CcSEcCtD
Vandetanib—Dizziness—Epirubicin—liver cancer	3.89e-05	0.000729	CcSEcCtD
Vandetanib—Pruritus—Doxorubicin—liver cancer	3.85e-05	0.000721	CcSEcCtD
Vandetanib—Vomiting—Epirubicin—liver cancer	3.74e-05	0.000701	CcSEcCtD
Vandetanib—Diarrhoea—Doxorubicin—liver cancer	3.72e-05	0.000698	CcSEcCtD
Vandetanib—Rash—Epirubicin—liver cancer	3.71e-05	0.000695	CcSEcCtD
Vandetanib—Dermatitis—Epirubicin—liver cancer	3.71e-05	0.000694	CcSEcCtD
Vandetanib—Headache—Epirubicin—liver cancer	3.68e-05	0.00069	CcSEcCtD
Vandetanib—Dizziness—Doxorubicin—liver cancer	3.6e-05	0.000674	CcSEcCtD
Vandetanib—Nausea—Epirubicin—liver cancer	3.49e-05	0.000654	CcSEcCtD
Vandetanib—Vomiting—Doxorubicin—liver cancer	3.46e-05	0.000648	CcSEcCtD
Vandetanib—Rash—Doxorubicin—liver cancer	3.43e-05	0.000643	CcSEcCtD
Vandetanib—Dermatitis—Doxorubicin—liver cancer	3.43e-05	0.000642	CcSEcCtD
Vandetanib—Headache—Doxorubicin—liver cancer	3.41e-05	0.000639	CcSEcCtD
Vandetanib—Nausea—Doxorubicin—liver cancer	3.23e-05	0.000606	CcSEcCtD
Vandetanib—LYN—Signaling Pathways—IL2—liver cancer	8.72e-07	8.14e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCND1—liver cancer	8.68e-07	8.11e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—JUN—liver cancer	8.66e-07	8.09e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—liver cancer	8.64e-07	8.07e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—MTHFR—liver cancer	8.64e-07	8.07e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CTNNB1—liver cancer	8.59e-07	8.03e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CASP3—liver cancer	8.59e-07	8.03e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—STAT3—liver cancer	8.58e-07	8.02e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL2—liver cancer	8.58e-07	8.01e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—liver cancer	8.55e-07	7.99e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HPGDS—liver cancer	8.54e-07	7.98e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—CDKN1A—liver cancer	8.52e-07	7.95e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCND1—liver cancer	8.5e-07	7.94e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—HRAS—liver cancer	8.48e-07	7.92e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—JUN—liver cancer	8.48e-07	7.92e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARA—liver cancer	8.47e-07	7.92e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HRAS—liver cancer	8.46e-07	7.9e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—BRAF—liver cancer	8.45e-07	7.89e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—KRAS—liver cancer	8.44e-07	7.89e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PIK3CA—liver cancer	8.44e-07	7.88e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MMP9—liver cancer	8.43e-07	7.87e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CTNNB1—liver cancer	8.41e-07	7.86e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CDKN1A—liver cancer	8.39e-07	7.84e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCND1—liver cancer	8.36e-07	7.81e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—PIK3CA—liver cancer	8.36e-07	7.81e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—JUN—liver cancer	8.35e-07	7.8e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—PIK3CA—liver cancer	8.33e-07	7.78e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KRAS—liver cancer	8.28e-07	7.74e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CTNNB1—liver cancer	8.28e-07	7.74e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—HRAS—liver cancer	8.28e-07	7.73e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—MYC—liver cancer	8.28e-07	7.73e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—RAF1—liver cancer	8.27e-07	7.72e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—HRAS—liver cancer	8.27e-07	7.72e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—TGFB1—liver cancer	8.26e-07	7.71e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MMP9—liver cancer	8.25e-07	7.7e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HRAS—liver cancer	8.24e-07	7.7e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—STAT3—liver cancer	8.23e-07	7.69e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CDKN1A—liver cancer	8.22e-07	7.68e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK8—liver cancer	8.19e-07	7.65e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—liver cancer	8.19e-07	7.65e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HRAS—liver cancer	8.18e-07	7.64e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—HRAS—liver cancer	8.15e-07	7.61e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—PIK3CA—liver cancer	8.13e-07	7.6e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP9—liver cancer	8.12e-07	7.59e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—liver cancer	8.12e-07	7.58e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KRAS—liver cancer	8.11e-07	7.58e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—liver cancer	8.09e-07	7.56e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CDKN1A—liver cancer	8.09e-07	7.56e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—liver cancer	8.09e-07	7.55e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MTOR—liver cancer	8.07e-07	7.54e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CB—liver cancer	8.07e-07	7.54e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PIK3CA—liver cancer	8.03e-07	7.5e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK8—liver cancer	8.02e-07	7.49e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—KRAS—liver cancer	7.98e-07	7.46e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MYC—liver cancer	7.98e-07	7.45e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RAF1—liver cancer	7.97e-07	7.44e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—TGFB1—liver cancer	7.96e-07	7.43e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—liver cancer	7.92e-07	7.4e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—liver cancer	7.91e-07	7.39e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CD—liver cancer	7.9e-07	7.38e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK8—liver cancer	7.9e-07	7.38e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—liver cancer	7.89e-07	7.37e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—liver cancer	7.83e-07	7.31e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SERPINE1—liver cancer	7.81e-07	7.3e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HRAS—liver cancer	7.81e-07	7.29e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—liver cancer	7.8e-07	7.29e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MTOR—liver cancer	7.78e-07	7.27e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CB—liver cancer	7.78e-07	7.27e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—liver cancer	7.77e-07	7.26e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PIK3CA—liver cancer	7.76e-07	7.25e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—HRAS—liver cancer	7.74e-07	7.23e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HRAS—liver cancer	7.71e-07	7.2e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—KRAS—liver cancer	7.65e-07	7.14e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	7.61e-07	7.11e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PSMD10—liver cancer	7.61e-07	7.11e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PSMA4—liver cancer	7.61e-07	7.11e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PIK3CA—liver cancer	7.61e-07	7.11e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—STAT3—liver cancer	7.6e-07	7.1e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDKN1B—liver cancer	7.57e-07	7.08e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—liver cancer	7.57e-07	7.07e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—HRAS—liver cancer	7.52e-07	7.03e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—liver cancer	7.51e-07	7.01e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—liver cancer	7.49e-07	7e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—STAT3—liver cancer	7.49e-07	7e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—liver cancer	7.47e-07	6.98e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—liver cancer	7.47e-07	6.97e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PIK3CA—liver cancer	7.45e-07	6.96e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HRAS—liver cancer	7.43e-07	6.94e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CASP3—liver cancer	7.42e-07	6.93e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL2—liver cancer	7.41e-07	6.92e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—liver cancer	7.41e-07	6.92e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GOT2—liver cancer	7.4e-07	6.92e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—liver cancer	7.38e-07	6.89e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—KRAS—liver cancer	7.37e-07	6.88e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—PIK3CA—liver cancer	7.33e-07	6.85e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—STAT3—liver cancer	7.33e-07	6.85e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—liver cancer	7.31e-07	6.83e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—liver cancer	7.3e-07	6.82e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDKN1B—liver cancer	7.3e-07	6.82e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—liver cancer	7.29e-07	6.81e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—liver cancer	7.28e-07	6.8e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CG—liver cancer	7.26e-07	6.78e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCND1—liver cancer	7.23e-07	6.75e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—liver cancer	7.22e-07	6.74e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—STAT3—liver cancer	7.22e-07	6.74e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—JUN—liver cancer	7.21e-07	6.74e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—liver cancer	7.2e-07	6.73e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—liver cancer	7.2e-07	6.72e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HRAS—liver cancer	7.18e-07	6.7e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CTNNB1—liver cancer	7.16e-07	6.68e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CASP3—liver cancer	7.15e-07	6.68e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL2—liver cancer	7.14e-07	6.67e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—liver cancer	7.11e-07	6.64e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—KRAS—liver cancer	7.07e-07	6.6e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MYC—liver cancer	7.06e-07	6.6e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RAF1—liver cancer	7.05e-07	6.59e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—TGFB1—liver cancer	7.04e-07	6.58e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HRAS—liver cancer	7.04e-07	6.58e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—PIK3CA—liver cancer	7.03e-07	6.56e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP9—liver cancer	7.02e-07	6.55e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARG—liver cancer	7e-07	6.54e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CDKN1A—liver cancer	6.99e-07	6.53e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCND1—liver cancer	6.96e-07	6.5e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP2E1—liver cancer	6.96e-07	6.5e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MYC—liver cancer	6.96e-07	6.5e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—JUN—liver cancer	6.95e-07	6.49e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TGFB1—liver cancer	6.94e-07	6.49e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HRAS—liver cancer	6.9e-07	6.44e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CTNNB1—liver cancer	6.9e-07	6.44e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—liver cancer	6.89e-07	6.44e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MTOR—liver cancer	6.89e-07	6.43e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CB—liver cancer	6.89e-07	6.43e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—liver cancer	6.87e-07	6.42e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—liver cancer	6.83e-07	6.38e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK8—liver cancer	6.82e-07	6.37e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MYC—liver cancer	6.81e-07	6.37e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—liver cancer	6.8e-07	6.36e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TGFB1—liver cancer	6.8e-07	6.35e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—HRAS—liver cancer	6.79e-07	6.34e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—PIK3CA—liver cancer	6.77e-07	6.32e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP9—liver cancer	6.76e-07	6.32e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—liver cancer	6.74e-07	6.29e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CDKN1A—liver cancer	6.74e-07	6.29e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MYC—liver cancer	6.71e-07	6.27e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TGFB1—liver cancer	6.69e-07	6.25e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—liver cancer	6.64e-07	6.21e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—liver cancer	6.6e-07	6.17e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK8—liver cancer	6.58e-07	6.14e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—liver cancer	6.56e-07	6.13e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—KRAS—liver cancer	6.52e-07	6.09e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYCS—liver cancer	6.51e-07	6.08e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—HRAS—liver cancer	6.5e-07	6.07e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—liver cancer	6.49e-07	6.07e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—PIK3CA—liver cancer	6.49e-07	6.06e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDKN1B—liver cancer	6.46e-07	6.04e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KRAS—liver cancer	6.43e-07	6.01e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GOT1—liver cancer	6.39e-07	5.97e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GGT1—liver cancer	6.39e-07	5.97e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CD—liver cancer	6.38e-07	5.96e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—liver cancer	6.34e-07	5.92e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CASP3—liver cancer	6.33e-07	5.92e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL2—liver cancer	6.32e-07	5.91e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—liver cancer	6.3e-07	5.88e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KRAS—liver cancer	6.3e-07	5.88e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—HRAS—liver cancer	6.26e-07	5.85e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PIK3CA—liver cancer	6.24e-07	5.83e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—STAT3—liver cancer	6.24e-07	5.83e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—liver cancer	6.22e-07	5.81e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—liver cancer	6.22e-07	5.81e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KRAS—liver cancer	6.2e-07	5.79e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCND1—liver cancer	6.17e-07	5.76e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—JUN—liver cancer	6.15e-07	5.75e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CTNNB1—liver cancer	6.11e-07	5.7e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—liver cancer	6.09e-07	5.69e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—liver cancer	6.07e-07	5.67e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—STAT3—liver cancer	6.01e-07	5.61e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—HRAS—liver cancer	6.01e-07	5.61e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—liver cancer	6e-07	5.6e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PIK3CA—liver cancer	5.99e-07	5.6e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—liver cancer	5.99e-07	5.6e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP9—liver cancer	5.99e-07	5.59e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CDKN1A—liver cancer	5.96e-07	5.57e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PIK3CA—liver cancer	5.91e-07	5.52e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK8—liver cancer	5.82e-07	5.44e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MYC—liver cancer	5.8e-07	5.41e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PIK3CA—liver cancer	5.79e-07	5.4e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TGFB1—liver cancer	5.78e-07	5.4e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—liver cancer	5.75e-07	5.37e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTP1—liver cancer	5.74e-07	5.36e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—liver cancer	5.74e-07	5.36e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—liver cancer	5.72e-07	5.34e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PIK3CA—liver cancer	5.7e-07	5.32e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HMOX1—liver cancer	5.66e-07	5.29e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—liver cancer	5.6e-07	5.23e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MYC—liver cancer	5.59e-07	5.22e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TGFB1—liver cancer	5.57e-07	5.2e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CB—liver cancer	5.56e-07	5.19e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—HRAS—liver cancer	5.55e-07	5.18e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—liver cancer	5.53e-07	5.17e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—liver cancer	5.51e-07	5.15e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3CA—liver cancer	5.49e-07	5.13e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HRAS—liver cancer	5.47e-07	5.11e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—liver cancer	5.37e-07	5.02e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KRAS—liver cancer	5.36e-07	5e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HRAS—liver cancer	5.35e-07	5e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—STAT3—liver cancer	5.32e-07	4.97e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—liver cancer	5.31e-07	4.96e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—liver cancer	5.3e-07	4.95e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GSTM1—liver cancer	5.28e-07	4.93e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HRAS—liver cancer	5.27e-07	4.92e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—liver cancer	5.23e-07	4.89e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KRAS—liver cancer	5.16e-07	4.82e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—liver cancer	5.12e-07	4.78e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—liver cancer	5.1e-07	4.76e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—liver cancer	5.04e-07	4.71e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP1A1—liver cancer	5e-07	4.67e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MYC—liver cancer	4.95e-07	4.62e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TGFB1—liver cancer	4.93e-07	4.61e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CA—liver cancer	4.92e-07	4.6e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—liver cancer	4.9e-07	4.57e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—liver cancer	4.83e-07	4.51e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—liver cancer	4.76e-07	4.45e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CA—liver cancer	4.74e-07	4.43e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—liver cancer	4.73e-07	4.41e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MTHFR—liver cancer	4.66e-07	4.36e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—liver cancer	4.65e-07	4.35e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—liver cancer	4.59e-07	4.28e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARA—liver cancer	4.57e-07	4.27e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KRAS—liver cancer	4.57e-07	4.27e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HRAS—liver cancer	4.55e-07	4.25e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—liver cancer	4.49e-07	4.19e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HRAS—liver cancer	4.39e-07	4.1e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—liver cancer	4.36e-07	4.07e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—liver cancer	4.2e-07	3.92e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CA—liver cancer	4.2e-07	3.92e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—liver cancer	4.06e-07	3.79e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—liver cancer	4.02e-07	3.75e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CG—liver cancer	3.92e-07	3.66e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HRAS—liver cancer	3.88e-07	3.63e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—liver cancer	3.87e-07	3.62e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARG—liver cancer	3.78e-07	3.53e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—liver cancer	3.72e-07	3.47e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CD—liver cancer	3.44e-07	3.22e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—liver cancer	3.43e-07	3.2e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALB—liver cancer	3.4e-07	3.18e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CA—liver cancer	3.39e-07	3.17e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CB—liver cancer	3e-07	2.8e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—liver cancer	2.77e-07	2.59e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CA—liver cancer	1.83e-07	1.71e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—liver cancer	1.49e-07	1.4e-06	CbGpPWpGaD
